Bone Response to GLP-1 Use in Women
Determine if bone density, bone microarchitecture, and estimates of bone strength change in response to 12 months of glucagon-like peptide-1 receptor agonist (GLP-1 RA)-induced weight loss in pre- and post-menopausal women.
Why this Research Matters
This study plans to learn more about bone and body composition changes when someone starts taking a glucagon-like peptide-1 receptor agonist (GLP-1) for weight loss. This information is important to understand how to develop different strategies to main bone and muscle during weight loss.
Who can Participate
Women between the ages of 25-45 OR 55-75 yrs Initiated a GLP-1 for weight loss within the previous 8 weeks No diagnosis of osteoporosis and/or use of osteoporosis medications No Type 1 Diabetes or Type 2 Diabetes if using insulin or canagliflozin Not currently pregnant or planning to become pregnant in the next 12 months
Study ID
Protocol Number: 25-0818
Meet the Team
Principal Investigator